Possis files for approval of AngioJet:
This article was originally published in Clinica
Executive Summary
US firm Possis Medical has submitted a premarketing approval application for its AngioJet thrombectomy system for removing blood clots from the arteries of patients suffering conditions such as heart attack and angina. In trials, the device performed better than treatment with the clot-dissolving drug urokinase. Minneapolis, Minnesota-based Possis has asked the FDA to give the device expedited review status.